Introduction
Rinvoq (upadacitinib) is an oral prescription medication used to treat several inflammatory and immune-mediated conditions. It belongs to a class of medications known as Janus kinase (JAK) inhibitors and works by affecting immune-system signaling pathways involved in inflammation. It is approved for several conditions, with the specific patient population and treatment requirements varying by indication.
This medication is available as extended-release tablets in 15 mg, 30 mg, and 45 mg strengths, as well as Rinvoq LQ oral solution. Certain approved indications include pediatric patients beginning at age 2, while others are approved only for adults or older pediatric patients.
Prescription Hope may help eligible patients navigate prescription assistance programs for Rinvoq and understand the enrollment process.
Rinvoq (upadacitinib) is an oral JAK inhibitor that targets immune-system signaling involved in inflammation and is approved for specific inflammatory and immune-mediated conditions. It is available as 15 mg, 30 mg, and 45 mg extended-release tablets and as Rinvoq LQ oral solution, with approved ages and treatment requirements varying by condition. For eligible patients seeking Rinvoq prescription assistance, Prescription Hope can provide support with Upadacitinib patient assistance applications and explain program options that may help pay for various brand-name medications, while eligibility and approval are determined by each program.
What Is the Rinvoq Patient Assistance Program?
Pharmaceutical manufacturers understand that not all of their products are affordable for average Americans. To help alleviate this burden, many manufacturers offer qualified patients access to patient assistance programs.
Once enrolled, patients receive access to their brand-name medication at affordable rates, allowing them to avoid expensive out-of-pocket costs.
However, patient assistance programs have been known to include rigorous standards, difficult to navigate processes, and extensive forms and documentation.
Thankfully, there is a solution.
How Expert Advocates Help Make Rinvoq More Affordable
Patient-Focused Medication Support
For more than 20 years, patients have trusted Prescription Hope for warm, patient-focused medication support. Our Florida-based medication assistance advocates provide personalized prescription assistance support, including patient support, to help eligible patients access the medications they need at a more affordable cost.
Simplified Access to Specialty Therapies
We’re here to make getting the medications you need feel easier and less stressful. Through personalized prescription support, specialty medication assistance, access to specialty medications, and specialty therapy assistance, we help lower medication costs so you can focus on your health with greater peace of mind.
Ongoing Prescription Assistance
Prescription Hope is here to support you beyond the initial application. Our ongoing prescription assistance and continued medication assistance include dedicated help from patient advocates with forms and documents, issue resolution, refill scheduling, and medication assistance renewal each year.
If you need affordable access to brand-name medications and compassionate prescription assistance support, enroll with Prescription Hope today.
Rinvoq Price Comparison
vs
Estimated Retail Price*
30-Day Supply
Prescription Hope Price
Per Month, NO Matter The Retail Price
*Source: Drugs.com
Rinvoq Patient Assistance Eligibility
Who qualifies for Rinvoq assistance? General Rinvoq patient assistance eligibility may depend on household income, insurance status, a valid Rinvoq prescription, and legal U.S. residency. Because Rinvoq assistance eligibility varies by program, Prescription Hope can help you understand prescription assistance eligibility and review your medication assistance qualifications under current program guidelines.
Simple Enrollment With Expert Support
Submit Your Information
To apply for brand-name medication assistance, submit your information through Prescription Hope’s secure online form. This first step in Rinvoq enrollment helps our team begin your assistance application, review the details needed for your prescription assistance application, and guide you through medication assistance enrollment.
Advocate Contact
After you submit the online form, a Prescription Hope advocate will contact you to review your information, explain next steps, and answer questions. Your prescription assistance advocate will provide personalized medication assistance support throughout the application process.
Document Collection
Next, your advocate will help identify and collect the prescription assistance documents needed for your medication assistance application, including any medication assistance paperwork required by the applicable program.
Provider Coordination
During healthcare provider coordination, your advocate works with your provider to request the signatures, documents, and Rinvoq prescription information needed to move the prescription assistance process forward. This medication assistance support helps keep communication organized while your healthcare provider remains responsible for reviewing and supplying the required clinical information.
Complete the Enrollment Process
Your advocate completes the enrollment process by finalizing and submitting your medication assistance application. The prescription assistance enrollment and medication assistance application are then reviewed by the applicable program.
Understanding Rinvoq
How Rinvoq Works
Rinvoq contains upadacitinib, a Janus kinase (JAK) inhibitor that affects signaling pathways used by cytokines and growth factors involved in immune-system activity and inflammation. Upadacitinib inhibits Janus kinase enzymes and reduces downstream signaling through STAT proteins. In laboratory assays, it showed greater inhibitory potency against JAK1 and JAK2 than JAK3 and TYK2, although the FDA labeling states that the relevance of inhibition of individual JAK enzymes to its therapeutic effectiveness is not currently known.
In simple terms, it works by blocking certain immune-system signaling pathways that contribute to inflammation.
What Conditions Does Rinvoq Treat?
Rinvoq is approved to treat several inflammatory and immune-mediated conditions. These include rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, Crohn’s disease, ankylosing spondylitis, non-radiographic axial spondyloarthritis, polyarticular juvenile idiopathic arthritis, and giant cell arteritis. The approved patient population and treatment-history requirements vary by condition.
Certain indications are approved for pediatric patients, including psoriatic arthritis and polyarticular juvenile idiopathic arthritis beginning at age 2. Other indications have specific adult or older-pediatric requirements.
Benefits of Treatment
Depending on the condition being treated, this medication may help reduce signs and symptoms of inflammatory arthritis, improve physical function, improve skin disease in appropriately selected patients with atopic dermatitis, or induce and maintain clinical response or remission in ulcerative colitis and Crohn’s disease. It may also improve symptoms and disease activity associated with ankylosing spondylitis and non-radiographic axial spondyloarthritis and help achieve sustained remission in adults with giant cell arteritis.
What is Rinvoq used for, and how can it help? It uses vary by diagnosis, but its approved applications focus on certain immune-mediated inflammatory conditions. Understanding how this medication works—by helping reduce specific immune-system activity—can provide context for the potential Rinvoq benefits your healthcare provider may consider when deciding whether treatment is appropriate for you.
Important Safety Information and Side Effects
Boxed Warning
Rinvoq carries an FDA Boxed Warning addressing serious infections, mortality, malignancy, major adverse cardiovascular events (MACE), and thrombosis. Serious bacterial, fungal, viral, and opportunistic infections, including tuberculosis, can occur and may lead to hospitalization or death. The mortality, malignancy, MACE, and thrombosis portions of the warning also reference findings from a large postmarketing safety study of another JAK inhibitor compared with TNF blockers in certain rheumatoid arthritis patients.
Serious Infections
This medication can increase the risk of serious infections. Patients should be evaluated for tuberculosis before treatment and monitored for infections during and after therapy. Medication literature recommends that treatment should be interrupted if a serious infection develops until the infection is controlled.
Malignancy and Lymphoproliferative Disorders
Malignancies, including lymphoma and other cancers, have occurred in patients treated with Rinvoq. The FDA labeling also identifies additional malignancy risk in current or former smokers based on JAK-inhibitor class safety findings.
Major Adverse Cardiovascular Events
Rinvoq’s labeling warns about major adverse cardiovascular events, including cardiovascular death, myocardial infarction, and stroke. The risk is particularly relevant to JAK-inhibitor safety findings in higher-risk rheumatoid arthritis patients. It is recommended that patients who experience a myocardial infarction or stroke should discontinue treatment.
Thrombosis
Deep vein thrombosis, pulmonary embolism, and arterial thrombosis have occurred in patients treated with JAK inhibitors, including Rinvoq. Many of these events were serious, and some resulted in death. The labeling advises avoiding taking this medication for patients at risk of thrombosis.
Hypersensitivity
Serious hypersensitivity reactions, including anaphylaxis, have been reported. This medication should be discontinued if a serious hypersensitivity reaction occurs.
Gastrointestinal Perforations
Gastrointestinal perforations have occurred in patients receiving this medication. Patients at increased risk should be monitored and promptly evaluated if symptoms suggest a gastrointestinal perforation.
Hypoglycemia in Patients With Diabetes
The June 2026 FDA labeling added a warning concerning hypoglycemia in patients with diabetes. Hypoglycemia, including severe hypoglycemia, has been reported following initiation of Rinvoq/Rinvoq LQ and other JAK inhibitors in patients with diabetes.
Laboratory Abnormalities
Rinvoq may affect neutrophil counts, lymphocyte counts, hemoglobin, liver enzymes, and lipid levels. Laboratory monitoring is recommended according to the prescribing information.
Embryo-Fetal Toxicity
Based on animal studies, upadacitinib may cause fetal harm. Females of reproductive potential should use effective contraception during treatment and for 4 weeks after the final dose.
Vaccinations
Patients should have appropriate immunizations updated before treatment when possible. Live vaccines should be avoided during treatment with Rinvoq/Rinvoq LQ.
Medication Residue in Stool
Medication residue, including an intact tablet or tablet fragments, has been observed in stool or ostomy output, particularly in patients with shortened gastrointestinal transit times. Patients should contact their healthcare provider if medication residue is observed repeatedly.
Retinal Detachment
Retinal detachment has been reported in clinical trials, including among patients treated for atopic dermatitis. Patients should promptly contact their healthcare provider if they experience sudden changes in vision.
Contraindications
Rinvoq and Rinvoq LQ are contraindicated in patients with known hypersensitivity to upadacitinib or any of the product’s excipients.
Drug Interactions
Strong CYP3A4 Inhibitors
Strong CYP3A4 inhibitors can increase upadacitinib exposure and may increase the risk of adverse reactions. The current label identifies ketoconazole and clarithromycin as examples and advises avoiding food or beverages containing grapefruit during treatment. Dosage modifications with strong CYP3A4 inhibitors vary by indication.
Strong CYP3A4 Inducers
Strong CYP3A4 inducers, such as rifampin, can reduce upadacitinib exposure and may decrease its effectiveness. Concomitant use is not recommended.
Pregnancy and Breastfeeding
Available human data are insufficient to determine the risk of major birth defects or miscarriage. Animal studies indicate the potential for embryo-fetal harm. Pregnancy status should be verified in females of reproductive potential before starting treatment, and effective contraception should be used during treatment and for 4 weeks after the final dose.
Breastfeeding is not recommended during Rinvoq treatment and for 6 days after the last dose because of the potential for serious adverse reactions in a breastfed infant. There are no adequate data regarding upadacitinib in human milk.
Common Side Effects
Common adverse reactions vary by indication. Across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis trials, reported adverse reactions included upper respiratory tract infections, herpes zoster, herpes simplex, bronchitis, nausea, cough, fever, acne, and headache. For giant cell arteritis, commonly reported adverse reactions included upper respiratory tract infection, headache, fatigue, peripheral edema, cough, anemia, rash, herpes zoster, and nausea.
Administration Information
Rinvoq is administered orally and may be taken with or without food. Rinvoq extended-release tablets are generally taken once daily and should be swallowed whole rather than split, crushed, or chewed. Dosing varies according to the condition being treated, and pediatric dosing for psoriatic arthritis and polyarticular juvenile idiopathic arthritis is based on body weight. Rinvoq LQ oral solution and Rinvoq extended-release tablets are not substitutable.
Dosage Forms and Strengths
Rinvoq is available as 15 mg, 30 mg, and 45 mg extended-release tablets. Rinvoq LQ is available as a 1 mg/mL oral solution.
Hepatic Impairment
Rinvoq/Rinvoq LQ is not recommended for patients with severe hepatic impairment (Child-Pugh C). The approach to mild and moderate hepatic impairment varies according to the indication.
Access to Multiple Medications
Need prescription assistance for multiple medications, including Rinvoq? Prescription Hope helps eligible patients explore participating medication assistance programs and understand the application requirements for each prescription.
Multiple medication assistance may help with prescription costs when support for more than one medication is appropriate. Prescription Hope’s services are provided for $70.00 per medication per month, while approval and continued participation are determined separately by each program.
Why Choose Prescription Hope for Medication Assistance?
Patient-Focused Medication Support
Prescription Hope patient support provides patient-focused medication support through Florida-based advocates. Our team offers personalized medication assistance, patient assistance, and ongoing medication assistance support to help patients navigate participating programs, with eligibility and approval determined by each program.
Simplified Access to Specialty Therapies
Prescription Hope offers specialty medication assistance to help patients explore access to specialty medications through participating programs. Our specialty medication assistance and personalized support can simplify the application process and help patients understand options for specialty therapy affordability, subject to program eligibility and requirements.
Ongoing Prescription Assistance
Prescription Hope provides long-term medication support beyond the initial application. Our ongoing prescription assistance and continued medication assistance include help from patient advocates with documents, issue resolution, refill scheduling, and prescription assistance renewal for prescription assistance, subject to program requirements.
If you need help navigating assistance for brand-name medications, learn more about Prescription Hope’s services and enrollment process today.